Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573421 | 0.81 | ADORA1 (0.52) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL23573299 | 0.77 | LMNA (0.45) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL23573333 | 0.76 | EPHX1 (0.41) | SMN1; SMN2LMNAKDM4ECYP1A2MEN1 | |
| SCHEMBL23573417 | 0.75 | KMT2A (0.54) | KDM4EKMT2AALDH1A1CYP2D6TSHR | |
| SCHEMBL2010745 | 0.75 | KDM4E (0.58) | SMN1; SMN2LMNAKDM4ECYP1A2MEN1 | |
| SCHEMBL3543194 | 0.74 | KMT2A (0.65) | SMN1; SMN2LMNAKDM4EKMT2AALDH1A1 | |
| SCHEMBL23573254 | 0.72 | EPHX1 (0.40) | SMN1; SMN2LMNAKDM4EMEN1KMT2A | |
| SCHEMBL14731487 | 0.72 | LMNA (0.70) | SMN1; SMN2LMNAKDM4ECYP1A2MEN1 | |
| SCHEMBL23573329 | 0.71 | CHRNA4 (0.53) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1806628 | 0.70 | LMNA (0.57) | SMN1; SMN2LMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | SMN1; SMN2 1090/4885LMNA 1383/4885KDM4E 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.